Dr. Tian Yu is a Molecular Biologist experienced with life science/healthcare startups, currently focusing on leading products development in Truckee Applied Genomics and developing tools to improve the current covid testing by making it more affordable, more reliable, and keeping health care professionals safe from accidental viral exposures. Dr. Yu received her Ph.D. in biochemistry, molecular biology & cell biology in 2018. She has been published on topics such as epigenetic research for the interplay of RNA modifications and circular RNAs in the journal Cell Research. Before joining TAG, Dr. Yu has previously worked as an Assistant Core Director at the Single-Cell Sequencing Core, University of Nevada school of medicine, and then Bioelectronica as the lead biochemist where her research focused on developing life science tools for improving the antibody discovery workflow. The platform which she helped develop is now being placed in research labs across the globe.
Clinical & Research Tools Showcase:
Truckee Applied Genomics, LLC
Truckee Applied Genomics, LLC (TAG) is based in Reno Nevada and develops and manufactures patented reagents to improve molecular tests of tissues and pathogens.
New COVID-19 Surveillance Workflow With TAG-NGPM+
TAG-NGPM+ is the first specimen collection and transport media designed to improve safety for patients and lab staff by quickly inactivating virus while maintaining the sensitivity of molecular and rapid protein-based antigen assays. We propose a COVID-19 testing workflow that is designed to provide timely and accurate test results to patients and help with variant monitoring for effective transmission prevention and control.
The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.